美国食品和药物管理局在检查后向卢宾的新泽西设施发出483表格, FDA issued Form 483 with observations to Lupin's New Jersey facility following an inspection.

美国食品和药物管理局在2026年4月的检查后向卢宾新泽西州的设施发出了483表格,其中包含三项观察. The U.S. Food and Drug Administration issued a Form 483 with three observations to Lupin’s New Jersey facility following an April 2026 inspection. 该公司确认将处理这些调查结果,并重申其对现行良好制造实践的承诺. The company confirmed it will address the findings and reaffirmed its commitment to current Good Manufacturing Practices. 这是在2026年3月针对卢平的印度工厂发布单独的483表之后. This follows a separate Form 483 issued in March 2026 for Lupin’s Indian plant.